Amneal, a fully-integrated pharmaceutical company focused on the development, manufacture and distribution of generic and specialty drug products, completed the acquisition of Kashiv Specialty Pharmaceuticals, a premier fully integrated specialty biopharmaceutical company, for $108m. "Our management and scientists are excited to be a part of Amneal Pharmaceuticals. Kashiv Specialty has helped Amneal develop many high value, complex generic products, and possesses tremendous know how and patented novel technologies for developing complex generic and specialty products. Going forward, Amneal will provide valuable strategic, operational, and infrastructure support for the rapid development and commercialization of our specialty portfolio, which consists of differentiated 505(b)2 products that will serve patient needs in neurology and endocrinology and provide significant organic growth for Amneal," Navnit Shah, Kashiv Specialty President and Chief Scientific Officer.